Board Member
Halozyme Therapeutics, Inc. (HALO)Equibles does not estimate personal net worth.
Get an email with a short summary when Halozyme Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get HALO alertsHelen Torley is recorded as Board Member at Halozyme Therapeutics, Inc. (HALO) since January 1, 2014 and CEO at Halozyme Therapeutics, Inc. (HALO). The newest filing on record that lists Helen Torley as CEO at Halozyme Therapeutics, Inc. (HALO) is dated March 23, 2026. The newest filing on record that lists Helen Torley as Board Member at Halozyme Therapeutics, Inc. (HALO) is dated March 26, 2021. The proxy statement of Halozyme Therapeutics, Inc. reports total compensation of $23,166,223 for Helen Torley in fiscal 2025, including a base salary of $1,000,000. Disclosed compensation is on record for 4 fiscal years. Helen Torley has spoken on 23 earnings calls and 5 other investor events across 1 company, most recently for Halozyme Therapeutics, Inc. on November 5, 2026. Halozyme Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Halozyme Therapeutics, Inc. includes Darren Snellgrove (CFO), Elaine D. Sun (CFO), Nicole LaBrosse (CFO) and 7 others.
“I'm pleased to report another exceptionally strong quarter for Halozyme, as more patients, physicians, and healthcare systems experience the benefits of subcutaneous delivery within hands.”
“Yeah, Halozyme is transforming how biologics are delivered subcutaneously, and we're entering just a terrific period of value creation as a result of that. How do we do this?”
“Yeah, for Hale and Rheim, I think where China is impacting us is obviously a lot of our large partners and partner targets are highly engaged with China in seeking to expand their pipeline.”
“Well for those less familiar with Halozyme we focus on subcutaneous drug delivery and we have four subcutaneous delivery technologies now. The first and the largest to date is Enhance and we also have an auto injector platform as well.”
“I am pleased to report our results from an exceptionally strong second quarter, led by Enhance royalty revenue growth and new deal momentum that resulted in meaningful upfront milestones.”
2014-01-01–present
Last confirmed March 26, 2021
Start not stated–present
Last confirmed March 23, 2026
Biotechnology · Healthcare
CEO, Board Member
2014-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Halozyme Therapeutics, Inc. (HALO) | President and Chief Executive Officer | $1,000,000 | $23,166,223 |
| 2024 | Halozyme Therapeutics, Inc. (HALO) | President and Chief Executive Officer | $960,000 | $12,741,421 |
| 2023 | Halozyme Therapeutics, Inc. (HALO) | President and Chief Executive Officer | $920,000 | $11,820,858 |
| 2022 | Halozyme Therapeutics, Inc. (HALO) | President and Chief Executive Officer | $871,732 | $9,696,978 |
